Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody. (30th September 2020)

• Record Type: Journal Article
• Authors: Pichler, Judith; Memaran, Nima; Huber, Wolf Dietrich; Aufricht, Christoph; Bidmon‐Fliegenschnee, Bettina
• Is Part Of: Acta pædiatrica. Volume 110:Number 2(2021)
• Page Start: 661
• Page End: 667
• Publication Date: 2020-09-30
• Subjects: adolescents -- clinical response -- Crohn's disease -- golimumab; Pediatrics -- Periodicals; Pediatrics; 618.92
• DOI: 10.1111/apa.15522
• Languages: English
• ISSNs: 0803-5253

Abstract

Abstract: Aim: Anti‐tumour necrosis factor (TNF)‐α drugs are effective treatments for the management of moderate/severe Crohn's disease (CD), but treatment failure is common. In the treatment of paediatric CD, there are no data about the use of a third introduced subcutaneous TNF antibody golimumab. Methods: We evaluated the efficacy of golimumab for adolescents with moderate/severe CD. Retrospective analyses were done in all 7 (5 girls) adolescents who received golimumab at a median age of 17 years for a median of 7.2 months. Paediatric Crohn's disease activity index (PCDAI), full blood count, inflammatory markers, use of corticosteroids and adverse events were recorded. Results: With golimumab, 5 of the 7 children were PCDAI responders and 2 entered remission (PCDAI <10). Faecal calprotectin was significantly reduced after 4 weeks compared to baseline. Out of five children, steroid withdrawal was possible in one and steroid reduction in two cases. There were no serious side effects. Conclusion: In moderate/severe CD, golimumab induced clinical remission with PCDAI response. Golimumab may be an effective rescue therapy in refractory CD.